Cyclic peptide antitumor agent from an ascidian

Details Cyclic peptide antitumor agent from an ascidian Cyclic peptide antitumor agent from an ascidian

1996-09-27

1998-11-03

Nutter, Nathan M.

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

Peptides with at least one nonpeptide bond other than a...

530317, 514 9, 514 10, 514 21, A61K 3800, C07K 500, C07K 700

Patent

active

058309969

ABSTRACT:
A purified bicyclic depsipeptide, vitilevuamide, from the ascidians Didemnum cuculliferum and Polysyncraton lithostrotum is disclosed. Vitilevuamide has antitumor activity as demonstrated by standard in vitro and in vivo assays. An anticancer composition is also disclosed, comprising an effective amount of vitilevuamide and an inert carrier. A method of treating cancer is also disclosed, comprising administering an anticancer composition comprising an effective amount of vitilevuamide and an inert carrier.

REFERENCES:
patent: 4948791 (1990-08-01), Rinehart, Jr. et al.

Affiliated with

Also associated with

Rating

Cyclic peptide antitumor agent from an ascidian does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic peptide antitumor agent from an ascidian, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic peptide antitumor agent from an ascidian will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-690199